MMRF Research: Selective Inhibition of HDAC6
From the Summer 2005 Newsletter of the Multiple Myeloma Research Foundation.
James E. Bradner, MD, Broad Institute of Harvard and MIT Project Title: Selective inhibition of HDAC6 in the treatment of Multiple Myeloma.
Abstract: Dr. Bradner's research will investigate how to block HDAC6, a gatekeeper that allows elimination of toxic proteins and prevents the permanent death of myeloma cells in patients on bortezomib (Velcade). His lab discovered the only drug against HDAC6, called tubacin, and has recently proved that this drug kills myeloma cells in Petri dishes and that when tubacin and bortezomib are combined, myeloma cells are killed more effectively. Dr. Bradner will use his funding to invoestigate over 10 more potent versions of tubacin that he has identified and bring the best candidate into the clinic.
James E. Bradner, MD, Broad Institute of Harvard and MIT Project Title: Selective inhibition of HDAC6 in the treatment of Multiple Myeloma.
Abstract: Dr. Bradner's research will investigate how to block HDAC6, a gatekeeper that allows elimination of toxic proteins and prevents the permanent death of myeloma cells in patients on bortezomib (Velcade). His lab discovered the only drug against HDAC6, called tubacin, and has recently proved that this drug kills myeloma cells in Petri dishes and that when tubacin and bortezomib are combined, myeloma cells are killed more effectively. Dr. Bradner will use his funding to invoestigate over 10 more potent versions of tubacin that he has identified and bring the best candidate into the clinic.
posted by gwg at 5:36 PM
0 Comments:
Post a Comment
<< Home